Retatrutide
GLP-1/GIP/Glucagon Triple Agonist
Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This 39-amino acid peptide with C18 fatty diacid conjugation represents the cutting edge of metabolic peptide research. It has demonstrated exceptional results in adiposity reduction in preclinical and clinical studies.
Key Benefits
Available Sizes
B2B Wholesale Only · For Research Use Only · COA Provided with Every Order
Product Description
Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This 39-amino acid peptide with C18 fatty diacid conjugation represents the cutting edge of metabolic peptide research. It has demonstrated exceptional results in adiposity reduction in preclinical and clinical studies.
Amino Acid Sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Leu-Asp-Lys-Ile-Ala-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln-NH₂
Molecular Information
Request a Wholesale Quote
Fill out the form and our B2B team will respond within 24 hours with pricing, MOQ, and availability for Retatrutide.
Related Research
Peer-reviewed scientific literature on Retatrutide from PubMed, NEJM, The Lancet, and other authoritative sources.
Research Use Only. The following citations are provided for informational purposes and represent independent scientific research. These studies do not constitute medical advice or claims about our products. All products are sold for research purposes only and are not intended for human use.
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
New England Journal of Medicine, 389: 514–526 (2023)
Retatrutide 12 mg produced a mean weight loss of 17.5% at 24 weeks, with a projected 24.2% reduction at 48 weeks—the highest weight loss reported for any obesity pharmacotherapy to date.
Glucagon Receptor Signaling and Energy Homeostasis: Implications for Triple Agonist Therapy
Müller TD, Finan B, Clemmensen C, et al.
Nature Reviews Endocrinology, 13: 728–749 (2017)
Glucagon receptor activation synergizes with GLP-1 and GIP pathways to enhance energy expenditure, reduce hepatic steatosis, and promote greater adiposity reduction than dual incretin agonism alone.
Citations sourced from PubMed / NCBI, New England Journal of Medicine, The Lancet, Nature, and other peer-reviewed publications. DOI links lead to original publisher pages.
Related Products
Semaglutide
GLP-1 receptor agonist for metabolic research and weight management applications.
Tirzepatide
Dual GIP/GLP-1 receptor agonist. Widely used in metabolic and weight management research.
Cagrilintide
Long-acting amylin analog peptide used in appetite and obesity-related studies.